AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10723884 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete Harmonic Wavelet Transform (DHWT)
Number of subjects: 40
Study 10723884 — intervention group
Group type: COMPARATOR
Intervention: Oximetry
Number of subjects: 40
Study 7864420 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg of mivacurium after 1.0 mg/kg of succinylcholine
Number of subjects: 40
Study 7864420 — intervention group
Group type: COMPARATOR
Intervention: 0.15 mg/kg of mivacurium without succinylcholine
Number of subjects: 40
Study 1785277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush
Number of subjects: 107
Study 1785277 — intervention group
Group type: COMPARATOR
Intervention: Papaplast
Number of subjects: 107
Study 7262517 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow duodenal perfusion rate of [14C]PEG in saline (0.25 ml/min)
Number of subjects: 6
Study 7262517 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast duodenal perfusion rate (3.0 ml/min)
Number of subjects: 6
Study 7262517 — intervention group
Group type: EXPERIMENTAL
Intervention: No transpyloric tubes present
Number of subjects: 6
Study 29471329 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 525
Study 29471329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study 28110628 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual glyceryl trinitrate (800 µg)
Number of subjects: 110
Study 28110628 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 110
Study 25703440 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX (Vivitrol®; Alkermes Inc.)
Number of subjects: 34
Study 25703440 — intervention group
Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 34
Study 23652894 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion with 8% SCA and liquid serum with 40% SCA
Number of subjects: 25
Study 23652894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 21849081 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone-artesunate (CDA) 2/2.5/4 mg/kg given once daily for three days
Number of subjects: 2045
Study 21849081 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone 2/2.5 mg/kg given once daily for three days
Number of subjects: 2045
Study 21849081 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-dose artemether-lumefantrine
Number of subjects: 2045
Study 19596586 — intervention group
Group type: EXPERIMENTAL
Intervention: pegfilgrastim primary prophylaxis (PP)
Number of subjects: 59
Study 19596586 — intervention group
Group type: COMPARATOR
Intervention: secondary prophylaxis (SP)
Number of subjects: 59
Study 17012630 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort Turbuhaler) 160/4.5 microg as needed
Number of subjects: 92
Study 17012630 — intervention group
Group type: COMPARATOR
Intervention: Formoterol (Oxis Turbuhaler) 4.5 microg as needed
Number of subjects: 92
Study 15532809 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy (CRT)
Number of subjects: 100
Study 15532809 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 100
Study 11128345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonremovable off-bearing fiberglass cast
Number of subjects: 50
Study 11128345 — intervention group
Group type: COMPARATOR
Intervention: Cloth shoe with a rigid sole and unloading alkaform insole
Number of subjects: 50
Study 11128345 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient acceptance score
Number of subjects: 50
Study 9282968 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflurax (1200 mg, two tablets four times daily for 4 weeks)
Number of subjects: 65
Study 9282968 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets four times daily for 4 weeks)
Number of subjects: 65
Study 8275907 — intervention group
Group type: COMPARATOR
Intervention: Schizophrenic group (N = 19)
Number of subjects: 19
Study 8275907 — intervention group
Group type: COMPARATOR
Intervention: Paranoid subgroup (N = 10)
Number of subjects: 19
Study 8275907 — intervention group
Group type: COMPARATOR
Intervention: Disorganized subgroup
Number of subjects: 19
Study 8275907 — intervention group
Group type: EXPERIMENTAL
Intervention: S.A.P.S. global score
Number of subjects: 19
Study 8275907 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of hospitalization
Number of subjects: 19
Study 8275907 — intervention group
Group type: EXPERIMENTAL
Intervention: Paranoid subgroup vs Disorganized subgroup
Number of subjects: 19
Study 2433098 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydromorphone hydrochloride 2 mg
Number of subjects: 12
Study 2433098 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydromorphone hydrochloride 4 mg
Number of subjects: 12
Study 29332671 — intervention group
Group type: EXPERIMENTAL
Intervention: Actical accelerometer
Number of subjects: 50
Study 29332671 — intervention group
Group type: COMPARATOR
Intervention: Actiwatch 2
Number of subjects: 50
Study 28679555 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice supplemented with 15 μg vitamin D3
Number of subjects: 335
Study 28679555 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuit supplemented with 15 μg vitamin D3
Number of subjects: 335
Study 28679555 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice supplemented with 15 μg vitamin D2
Number of subjects: 335
Study 28679555 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuit supplemented with 15 μg vitamin D2
Number of subjects: 335
Study 28679555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 26165782 — intervention group
Group type: EXPERIMENTAL
Intervention: Training session and three emails about the colorectal cancer screening program
Number of subjects: 12
Study 26165782 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study 23043428 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial/ethnic discrimination (any frequency)
Number of subjects: 2490
Study 23043428 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial/ethnic discrimination (frequent and disturbing)
Number of subjects: 2490
Study 23043428 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial/ethnic discrimination (at least occasional)
Number of subjects: 2490
Study 21080844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow cell transplantation
Number of subjects: 0
Study 21080844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cell treatment)
Number of subjects: 0
Study 21080844 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IGF-1 levels above or below median)
Number of subjects: 0
Study 18227359 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored computer program for self-management goals for nutrition and physical activity, reviewed at each clinic visit
Number of subjects: 310
Study 18227359 — intervention group
Group type: COMPARATOR
Intervention: Printed health education materials
Number of subjects: 310
Study 16932286 — intervention group
Group type: COMPARATOR
Intervention: Alendronate and risedronate (oral nitrogen-containing bisphosphonates)
Number of subjects: 0
Study 16932286 — intervention group
Group type: COMPARATOR
Intervention: Ibandronate (oral, once-monthly dose of 150 mg)
Number of subjects: 0
Study 16932286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bisphosphonates (currently under investigation)
Number of subjects: 0
Study 14966716 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based resistance exercise program (lower-extremity resistance training 3 times a week)
Number of subjects: 29
Study 14966716 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained current level of physical activity)
Number of subjects: 29
Study 11158415 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmun Neoral with grapefruit juice
Number of subjects: 8
Study 11158415 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun Neoral with water
Number of subjects: 8
Study 9550632 — intervention group
Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (L‐NMMA, 3 mg/kg priming dose plus 3 mg/kg/h) for 3 hours
Number of subjects: 9
Study 7914620 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive algorithm based on neonatal body measurements (head circumference ≤31 cm or chest circumference ≤30 cm)
Number of subjects: 843
Study 7914620 — intervention group
Group type: COMPARATOR
Intervention: Validation group testing of the predictive algorithm
Number of subjects: 843
Study 3276343 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (Augmentin)
Number of subjects: 108
Study 3276343 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 108
Study 29344579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, Adriamycin, and dexamethasone followed by bortezomib maintenance after tandem autologous transplantation
Number of subjects: 0
Study 29344579 — intervention group
Group type: COMPARATOR
Intervention: Vincristine, Adriamycin, and dexamethasone
Number of subjects: 0
Study 29344579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 28850790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored program outreach messages containing content tailored to EHR-derived diabetes risk factors
Number of subjects: 35
Study 28850790 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication from personal physicians
Number of subjects: 35
Study 28850790 — intervention group
Group type: EXPERIMENTAL
Intervention: Careful development of messages to mitigate concerns over privacy and authenticity
Number of subjects: 35
Study 28850790 — intervention group
Group type: EXPERIMENTAL
Intervention: Techniques to counteract the threatening nature of personalized risk communication
Number of subjects: 35
Study 25850881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 25850881 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 420
Study 25850881 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 420
Study 25850881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 30 mg
Number of subjects: 420
Study 25850881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg
Number of subjects: 420
Study 25850881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 30 mg/Amlodipine 5 mg
Number of subjects: 420
Study 25850881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 30 mg/Amlodipine 10 mg
Number of subjects: 420
Study 25850881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg/Amlodipine 5 mg
Number of subjects: 420
Study 25850881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg/Amlodipine 10 mg
Number of subjects: 420
Study 23932998 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal implementation intentions
Number of subjects: 0
Study 23932998 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual implementation intentions
Number of subjects: 0
Study 23932998 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined verbal-visual implementation intentions
Number of subjects: 0
Study 23932998 — intervention group
Group type: COMPARATOR
Intervention: Control group (no implementation intentions)
Number of subjects: 0
Study 21242819 — intervention group
Group type: EXPERIMENTAL
Intervention: EPT (50 μg transdermal estradiol daily and 200 mg/d micronized progesterone for the first 14 days of each month; n = 21)
Number of subjects: 59
Study 21242819 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg daily; n = 17)
Number of subjects: 59
Study 21242819 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment; n = 21)
Number of subjects: 59
Study 18422829 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine treatment
Number of subjects: 515
Study 16731125 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 25
Study 16731125 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 25
Study 12556778 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-bite technique (4 specimens, 2 passages)
Number of subjects: 16
Study 12556778 — intervention group
Group type: COMPARATOR
Intervention: Single-bite technique (2 specimens)
Number of subjects: 16
Study 12556778 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-bite technique (first samples)
Number of subjects: 16
Study 12556778 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-bite technique (second samples)
Number of subjects: 16
Study 12556778 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps without a spike
Number of subjects: 16
Study 12556778 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiked forceps
Number of subjects: 16
Study 12556778 — intervention group
Group type: COMPARATOR
Intervention: Two-bite technique vs. single-bite technique
Number of subjects: 16
Study 12556778 — intervention group
Group type: EXPERIMENTAL
Intervention: Three types of forceps
Number of subjects: 16
Study 10686961 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 436
Study 10686961 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein (CRP)
Number of subjects: 436
Study 10686961 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-6 (IL-6)
Number of subjects: 436
Study 10686961 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 436
Study 9343463 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb (120 mg/d)
Number of subjects: 309
Study 9343463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 8170559 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbinil
Number of subjects: 497
Study 8170559 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 497
Study 3024689 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 6
Study 3024689 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 90 mg
Number of subjects: 6
Study 3024689 — intervention group
Group type: COMPARATOR
Intervention: Triprolidine 10 mg (active control)
Number of subjects: 6
Study 29443533 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga exercise with nutritional guidance
Number of subjects: 400
Study 29443533 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga exercise alone
Number of subjects: 400
Study 29443533 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional guidance alone
Number of subjects: 400
Study 29443533 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 400
Study 27261562 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Cognitive Behaviour Therapy (TD‐CBT)
Number of subjects: 233
Study 27261562 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorder-specific Cognitive Behaviour Therapy (DS‐CBT)
Number of subjects: 233
Study 27261562 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-guided Cognitive Behaviour Therapy (CG‐CBT)
Number of subjects: 233
Study 27261562 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided Cognitive Behaviour Therapy (SG‐CBT)
Number of subjects: 233
Study 25173752 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-2 administration
Number of subjects: 6
Study 25173752 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-2 administration 7 hours after a high-fat meal
Number of subjects: 6
Study 21720440 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg TE
Number of subjects: 158
Study 21720440 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg TE
Number of subjects: 158
Study 21720440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg TE
Number of subjects: 158
Study 21720440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 21720440 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 or 1.0 mg TE (Part 2)
Number of subjects: 158
Study 20685494 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS) 10 to 40 microg/h
Number of subjects: 78
Study 20685494 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS)
Number of subjects: 78
Study 20685494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 18435869 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect-focused body psychotherapy (ABP)
Number of subjects: 43
Study 18435869 — intervention group
Group type: COMPARATOR
Intervention: Standard psychiatric out-patient treatment (Control)
Number of subjects: 43
Study 15939681 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK solution (300 g glucose + 50 IU crystallized insulin + 80 mEq potassium chloride in one liter solution)
Number of subjects: 81
Study 15939681 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional treatment)
Number of subjects: 81
Study 15939681 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK solution
Number of subjects: 81
Study 15939681 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 12836501 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization appliance
Number of subjects: 60
Study 12836501 — intervention group
Group type: COMPARATOR
Intervention: Non-occlusal appliance
Number of subjects: 60
Study 10870743 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 0
Study 10870743 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 0
Study 10870743 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 10870743 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0
Study 8662400 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 30
Study 8662400 — intervention group
Group type: COMPARATOR
Intervention: Open hernia repair (Shouldice repair)
Number of subjects: 30
Study 8662400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 1831015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg, n = 18)
Number of subjects: 36
Study 1831015 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 36
Study 6137856 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1.5-3 mg per day
Number of subjects: 46
Study 6137856 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 15-30 mg per day
Number of subjects: 46
Study 6137856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31863809 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofluoric acid etching followed by silanization for polymer-infiltrated ceramic (PIC) and glass ceramic (VS)
Number of subjects: 300
Study 31863809 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond bur + SBU for resin composite (RC)
Number of subjects: 300
Study 31863809 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ aging
Number of subjects: 300
Study 31863809 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface treatment
Number of subjects: 300
Study 31863809 — intervention group
Group type: EXPERIMENTAL
Intervention: CFU/mL
Number of subjects: 300
Study 30683137 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (2 cycles of 1 MAC isoflurane administered 5 minutes prior to incision)
Number of subjects: 30
Study 30683137 — intervention group
Group type: COMPARATOR
Intervention: Propofol (3-5 mg/kg/h intravenous injection for the duration of surgery)
Number of subjects: 30
Study 29460154 — intervention group
Group type: EXPERIMENTAL
Intervention: Two non-compression miniplates (Group I)
Number of subjects: 28
Study 29460154 — intervention group
Group type: COMPARATOR
Intervention: Single non-compression miniplate (Group II)
Number of subjects: 28
Study 26361060 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 32
Study 26361060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 24129991 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided games (SGG)
Number of subjects: 18
Study 24129991 — intervention group
Group type: COMPARATOR
Intervention: High-intensity interval training (HIT)
Number of subjects: 18
Study 22369558 — intervention group
Group type: EXPERIMENTAL
Intervention: Periosteal pedicle graft (PPG)
Number of subjects: 20
Study 22369558 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 20
Study 20667921 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) for at least 6 hours per day
Number of subjects: 110
Study 20667921 — intervention group
Group type: COMPARATOR
Intervention: Standard care (incubator or open care system)
Number of subjects: 110
Study 17430323 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol, 1 mg/kg
Number of subjects: 60
Study 17430323 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%, 2 ml
Number of subjects: 60
Study 16015252 — intervention group
Group type: EXPERIMENTAL
Intervention: Child plasma selenium levels
Number of subjects: 610
Study 12240567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellous, slivered iliac bone grafts and stabilization with rush-pins used as intramedullary nails in 12 cases, in addition to plaster of paris casts.
Number of subjects: 125
Study 12240567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellous, slivered iliac bone grafts
Number of subjects: 125
Study 12240567 — intervention group
Group type: COMPARATOR
Intervention: Initial management with circular POP with windows for wound care or posterior slabs made of POP, Cramer‐wire, or wood at random.
Number of subjects: 125
Study 10695457 — intervention group
Group type: COMPARATOR
Intervention: Single-coil, unipolar configuration (active can alone)
Number of subjects: 27
Study 10695457 — intervention group
Group type: EXPERIMENTAL
Intervention: High SVC coil position
Number of subjects: 27
Study 10695457 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SVC coil position
Number of subjects: 27
Study 9187591 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 30 mmol (7.5 g) daily for 3 days
Number of subjects: 44
Study 9187591 — intervention group
Group type: COMPARATOR
Intervention: Normal saline equivalent to magnesium sulfate
Number of subjects: 44
Study 1328366 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment based on weight reduction and sodium restriction
Number of subjects: 64